medicines for europe
better access. better health.

16th Legal Affairs Conference

Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE 2022 - WITH WELCOME DINNER SESSION ON 28 JUNE - #LAC22

SPEAKERS AND CHAIRPERSONS

Paul Csiszar, Director, DG Competition, European Commission

Paul Csiszár is Director of Basic Industries, Manufacturing and Agriculture at the Directorate Generale for Competition of the European Commission in Brussels. After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the Bar in 1986 in California he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Central Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector.

Kristof Roox, Partner, Crowell & Moring

Kristof Roox is co-managing partner of Crowell & Moring's Brussels Office. He is a partner in the Intellectual Property Group and focuses on IP litigation, and in particular on complex patent litigation in the life sciences sector. With over 25 years of experience, Kristof has an impressive reputation before the Belgian civil and administrative courts, and before regulatory authorities. He is also widely respected for his pragmatic and creative approach to solving business disputes and for his to-the-point counselling. In addition to traditional IP litigation and counselling, Kristof is widely recognized for his thought leadership in relation to the regulatory aspects of life sciences. He advises companies and trade associations on launch and marketing strategies, parallel imports, promotional practices, rebates, pricing and reimbursement, distribution models, OTC products, health care reforms, competition law aspects, etc. Furthermore, Kristof is an experienced litigator across a broad range of commercial and civil matters, covering all aspects of dispute resolution including arbitration. With his deep knowledge of private international law issues, he often tackles complex multi-jurisdictional questions and he is reputed for his broad knowledge of procedural law issues.

Yuanqiong Hu, IP Senior Legal and IP Advisor, Médecins Sans Frontières

Hu Yuanqiong is a lawyer and Postdoctoral Research Associate at the School of Law, SOAS. Yuan works as Senior Legal and Policy Advisor for the Access Campaign of Médecins Sans Frontières (MSF/Doctors without Borders) with a focus on access to medicines and intellectual property, providing legal advice related to multiple jurisdictions including India, South Africa, China, Brazil, US, South Korea and the European Patent Office. She worked as Teaching Fellow in intellectual property law at Durham University, and completed her PhD in Law at SOAS on "Rethinking Patent Centric Biomedical Innovation: Towards an Alternative Conceptual Framework Building" in 2018. Yuan's current research focuses on reconceptualising biomedical innovation, with a critical and interdisciplinary approach to the intersections and co-production of law, society, science and technologies. She interrogates the role of expertise and professions in norm making and aims to explore the alternative conceptual framework for biomedical innovation in contrast to the patent centric paradigm. She is also interested in and has research experiences in international human rights law, public international law and international environmental law. Yuan has published several articles on the topic of intellectual property and access to medicines, including a co-authored article of 'Medical Patents and the Right to Health – From Monopoly Control to Open Access Innovation and Provision of Medicines' published on the German Yearbook of International Law, Vol 61 (2019), and "Resistance and Consistent: Access to Medicines and Patent Law Reforms in India and China", No.3 (2016) SOAS Law Working Paper Series. She also presented several conference papers based on her research, including the recent papers of 'Communities, Properties and Biomedical Knowledge through International Human Rights Lens' presented at the Conference of 'Protecting Community Interests under International Law: Challenges and Prospects for the 21st Century' at the Norwegian Centre for Human Rights, University of Oslo in June 2019, 'Realignment of Innovators: Patents, Norms and Social-Technical Creativities in Biomedicine' and 'The Role of Legal Profession and Expertise in Patent and Biomedical Innovation Discourse' presented at the Socio-Legal Studies Association Annual Conference in April 2019, University of Leeds. Previously, Yuan also conducted consultancies for Asia and Pacific Regional Office of United Nations Development Programme (UNDP), MSF and Third World Network on patent and access to medicines, and for Save the Children UK on post-2015 development policies.

Yannis Natsis, Director, European Social Insurance Platform (ESIP)

Yannis Natsis is the Director of the European Social Insurance Platform (ESIP), the umbrella organisation bringing together 45 national statutory social security institutions from 18 countries. ESIP is the voice of social protection and security in Europe or as Yannis puts it one of Europe's truest treasures. He has more than 10 years of experience in EU advocacy and policymaking. Prior to joining ESIP in February 2022, he led the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). In May 2019, he was appointed by EU Member States to the Management Board of the European Medicines Agency (EMA), a position he held until December 2021. Additionally, Yannis has been a Board member of the European Health Forum Gastein (EHFG), the leading EU health policy platform since 2018. Yannis previously worked for the TransAtlantic Consumer Dialogue (TACD) focusing on health and pharmaceutical policies. From 2006-2010, he was an investigative reporter for Greece's award-winning TV news programme "Fakeli" and a contributor to one of Greece's most respected dailies "Kathimerini". He has a Master's degree in International Conflict Analysis from the University of Kent, UK and a Bachelor's degree in European Studies from Pantion University of Social and Political Sciences, Athens, Greece. A Greek national, he is fluent in Greek, English and French.

Elena Moya, Spanish Patients' Association, Member of European Patients Forum

Elena Moya is a survivor of meningococcal meningitis, contracted at the age of 4. She fully recovered without secuelae thank to seeking medical help on time. Since then, she is very concerned about this disease. For the rest of her life, Elena will work to tell other families about the disease, to get their children vaccinated and to rush to the closest hospital as soon as they recognise the symptoms. She is a philologist and has been working for more than 25 years as a teacher of Spanish and French Literature. She studied 2 masters as Expert Manager in Patients Organisations and has been working as the African and European coordinator for the past 13 years. Her task is to coordinate the activities and strategic plans of 21 patients organisations in 12 countries. She is also the Vice President of the AEM (Asociación Española contra la Meningitis), unique association that fights against this disease in Spain. Now she plays a critical role in building awareness of meningitis across Spain through her visits to schools, hospitals, ministers and clinics. She has been trained to develop the best advocacy strategy in her country. She fights for equal access to immunisation as the only way to be protected against bacteria or virus. Elena was chosen to be part of FEP (Foro Español de Pacientes) Board of Directors in 2018 as their International Coordinator and since then she has been actively participating in EPF ś activities. She has also been recently nominated to be member of the Board of Directors of the Boston Scientific Foundation. Since 2020 she is proud to be able to help to choose the best projects that make a change in children's health. Her last outcome was to participate with the www.who.int to launch a roadmap to defeat meningitis in 2030. This historic decision and plan #defeatMeningitis recognise the fight of millions of persons affected by this disease. .

George Moore, Assistant General Counsel – Europe IP, Ex-NA IP Litigation – Viatris

George Moore is Assistant General Counsel - Europe IP, Ex-NA IP Litigation, at Viatris. He currently leads the IP team at Viatris for Europe and the IP Litigation function for all ROW matters. He is a qualified solicitor (England & Wales) with a masters' degree in chemistry. He has over 14 years in-house pharmaceutical experience, having worked at Apotex in Canada and Sandoz in Germany. He previously worked in private practice in the UK, training and qualifying at Bristows, before then working at Allen & Overy.

Alpha Indraccolo, VP and General Counsel, European IP and Regulatory Litigation, Teva

Alpha Indraccolo joined the European IP and Regulatory Litigation team at Teva in 2013. She has lead the team since 2018 covering matters relating to IP and regulatory litigation as well as support to IP aspects of government affairs in the European region. Alpha is a qualified solicitor (England & Wales) with a MSc in Molecular Biology from New York University and a BA from Barnard College. Before joining Teva, Alpha worked in private practice at Bird & Bird, London specialising in patent litigation.

Sergio Napolitano, General Counsel and External Relations Director, Medicines for Europe

Sergio Napolitano is General Counsel and External Relations Director at Medicines for Europe. At Medicines for Europe since January 2013, in 2018 he was nominated in a list of the 50 most influential people worldwide in IP law, policy and business. Before joining Medicines for Europe, Sergio Napolitano worked in the Directorate General for External Policies of the European Parliament and at the Permanent Representation of Italy to the EU on multilateral, plurilateral and bilateral trade negotiations, EU investment policy and IPR. Sergio Napolitano holds a degree in Law from the University of Naples Suor Orsola Benincasa and a LL.M. on EU and European Public Law from the University College of London (UCL).

Elisabeth Stampa, President, Medicines for Europe

With more than twenty years in the industry, Elisabeth is currently CEO of Medichem SA and serves on its Board. Since 2016, together with the Executive team, she has transformed the company from a pure API player into a vertically integrated B2B company. She has driven both innovation and sustainability initiatives within Medichem SA. Prior to becoming CEO, Elisabeth was Executive Chair of the Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career in Marketing at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and an MBA (ESADE Business School, Barcelona, Spain). She also serves on the Board of Trustees at the IQS in Barcelona. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level. She represented EU API manufacturers on behalf of EFCG in the GDUFA II negotiations with FDA.

David Rose, Partner, Mishcon de Reya LLP

David is a Partner in the Intellectual Property Department and heads up the firm's Patent Group. His practice focuses on clearing, protecting and enforcing IP rights. David is a highly experienced litigator and one of only a small number of IP lawyers in the UK who have taken both patent and trade mark cases to the Court of Justice of the European Union.

He has acted in a number of high profile and often ground-breaking cases before both the UK and European Courts including successfully representing Sky in the first passing off case to reach the UK's highest court (the Supreme Court) in over 25 years (Starbucks v. Sky) and acting for Nintendo in securing the first ever blocking injunction against ISPs in reliance on technological protection measures under the UK's copyright legislation. Additional high profile actions include: HTC v Gemalto; Sky v Microsoft; Napp v Sandoz; ratiopharm v Alza; Sky v Skype; Marks & Spencer and others v One in a Million; Lupin v. Gilead; Ann Taylor v. Holzer; Sony Computer Entertainment v Pacific Game Technology; Racing UK v Satellite Information Services; Arrow Generics v Merck; Cairnstores v Astra Zeneca; and Servier v Lupin; Warner-Lambert v Dr Reddy's Laboratories Limited; easyGroup v. Nuclei and IWG. In the patent sphere, David advises on infringement, validity and ownership disputes, the scope of protection of Supplementary Protection Certificates (SPCs) and disputes over standard essential patents (SEPs) including their licensing on FRAND terms (principally for implementers).

He also has considerable experience advising on "clearing the way" strategies in relation to pharmaceutical patents. Recent representations include acting for Lupin in its successful application to revoke Gilead's SPC for the HIV treatment Truvada® following hearings before the Grand Chamber of the Court of Justice of the EU and the Court of Appeal in London. In the area of brand and design protection, David has extensive experience advising on brand and design portfolio management with particular expertise acting in administrative proceedings before the UKIPO and the EUIPO and their respective appellate tribunals, including appearing successfully in numerous cases before the General Court of the EU. David is one of only eight UK IP lawyers listed in the Legal 500 "Hall of Fame", is ranked as a leading individual in Chambers (IP, life sciences and patent litigation), IAM Patent 1000 (patents and life sciences), Who's Who Legal (patents, life sciences and trade marks) and is recognised as one of World Trademark Review's "Global Leaders". Recent commentary from the directories includes: "tough as nails... a 'natural litigator' who is 'experienced and aggressive" (World Trademark Review); "a real client's lawyer, always very tenacious in looking after their interests…He is good to work with and gets the best out of his team." and "has impeccable judgement on strategic matters" (Chambers); "outstanding experience in this arena makes him a force of nature in the courtroom" (IAM Patent 100). David was recognised as the UK Practitioner of the Year at the 2020 Annual Managing IP EMEA Awards. David has a Master's Degree in Intellectual Property from the University of London and writes widely on IP matters in a range of journals including EIPR, BioScience Law Review, JIPLP and MIP. He is a member of CIPA, CITMA, AIPPI and INTA.

Soledad Cabezón Ruiz, former Member of the European Parliament

Soledad graduated in Medicine and Surgery, specializing in Cardiology. She began her political career at the municipal level in 2003, serving as mayor of Albaida del Aljarafe between 2003 and 2011. She held the secretariat for Equality Policies of the PSOE between 2008 and 2012. Later, elected deputy of the European Parliament in the European elections of 2014, she was integrated into the eighth legislature of the European Parliament within the political group of the Group of the Progressive Alliance of Socialists and Democrats between 2014 and 2019.

Alfonso Calles-Sánchez, Administrator, DG GROW, European Commission

Alfonso Calles-Sánchez works as an administrator in the “Intangible economy unit” of the Directorate General for Internal Market, Industry, Entrepreneurship and SMEs of the European Commission. He deals with the industrial scale up of COVID-19 vaccines and patent policy, especially EU pharmaceutical patent policy (SPC regulations, paediatric extensions and the SPC waiver). He has been a consultant on IPR for the United Nations Development Programme, and as a visiting scholar at Duke University he researched on policy instruments for the development of medicines for neglected diseases. He started his career in the IP field as a patent examiner in the Spanish Patent and Trademark Office in 2000. Alfonso is an industrial engineer from Universidad Politécnica de Madrid and holds a diploma on public administration from IESE Business School.

Miguel Vidal-Quadras, Partner, Vidal-Quadras & Ramon

Miguel has a PhD in law and is a founding partner of Vidal-Quadras & Ramon. He has been a lecturer in patent law at the University of Barcelona and ESADE since 2002 and has been teaching commercial law at the Universitat Internacional de Catalunya in Barcelona since 2012. As scholar he has published several books and articles on patent law and tech transfer, including Analysis of EU Regulation 2019/933 on the SPC Manufacturing Waiver Exception on September 2019 in IIC. He has assisted the interests of the Spanish manufacturers in the implementation of the bolar clause in Spain in 2006, the drafting of the Spanish Patent Act of 2015 and more recently the approval of the SPC waiver Regulation in 2019.

Karin Pramberger, Head of IP, Polpharma Group

Karin joined the Polpharma Group as Head of IP in 2018. She is responsible for all global patent and trade mark related activities. Prior to joining the Polpharma Group, Karin worked in various positions in the patent departments of Pharmaceutical companies after having spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she is a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam, and since 2006 she is an active member of the Legal Affairs Committee of Medicines for Europe.

Elizabeth Wright, Senior Counsel, European IP and Regulatory Litigation, Teva

Elizabeth Wright joined the European Regulatory and IP Litigation team at Teva Pharmaceuticals in 2020. She takes the lead for all regulatory litigation and legal support in Europe, as well as covering government affairs and IP litigation matters. Elizabeth is a qualified solicitor advocate (England & Wales) with a PhD in Genetics from Cambridge University. Before joining Teva, she spent 10 years working in private practice at Bird & Bird.

Matthew Royle, Partner, Taylor Wessing

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice. Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly. A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaceutical, biotech and life sciences sectors. He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.

Benjamin May, Partner, ARAMIS Société d'Avocats

One of the founders of Aramis law firm in Paris, Benjamin May was admitted to practice law in 2000 and further admitted to the panel of "IP specialists" with the Bar Association. Practice head of IP, Benjamin specializes in cross-border patent litigation with a focus on life sciences. Recognized by Legal 500 and Chambers as leading individual in patent litigation in 2022, Benjamin is a regular speaker in various IP & life sciences forums and also the author of several publications, e.g., in 2021 and 2022 "*Patent litigation in France*", "*Patent infringement damages in France: The "increased royalty" method leads to enhanced damages*", "*Digital therapeutics: What protection does intellectual property offer?*". Ranked by JUVE among the best law firms in France for patent litigation in 2022, the team at Aramis focuses on patent strategies, IP & trade secrets litigation, damages assessment, regulatory/marketing/ anti-trust matters, R&D and licensing agreements. The team has been involved in several of France and Europe's 2021 top 10 patent cases ranked by JUVE, highlighting that "*its patent litigation experience is almost exclusively based on the French part of international cases, what sets the team apart from competitors of a similar size in national French firms*". Contact: may@aramis-law.com

Dr. Anja Lunze, LL.M., Partner, Taylor Wessing

Anja co-heads the Life Sciences & Healthcare group in Germany. She is a specialist lawyer for intellectual property law and has been working in the area of patent law for over 16 years. Anja manages and coordinates complex, multinational patent infringement proceedings and drafts infringement and nullity opinions. She advises on parallel opposition and nullity proceedings before the European Patent Office, the Federal Patent Court and the Federal Supreme Court. In particular, Anja represents clients from the fields of pharmaceuticals, biotech, personalised medicine and precision medicine as well as from the chemical and medical device industries and advises on related issues of digitisation. Having spent time in Geneva, Strasbourg, Tokyo and London, Anja has intercultural competence and language skills (including English, French and Japanese). Her doctoral thesis on the legal consequences of the revocation of patents was awarded the Doctoral Prize of the Technical University Dresden.

Rainer Becker - Head of Unit DG COMP, European Commission

Rainer Becker leads the team in charge of the European Commission's antitrust enforcement in the area of pharmaceuticals and health. Recent investigations include pay-for-delay and excessive pricing cases. He has extensive competition law experience, from both public and private practice. Prior to his current position, Rainer led the unit coordinating the Commission's antitrust cases and developing competition policy in this area. He also served in different other functions in the Commission, developing, for instance, the EU legislation on facilitating the compensation of victims of competition infringements and working on antitrust and merger cases in manufacturing and consumer goods industries. Before joining the Commission in 2004, Rainer was a senior associate in an international law firm, where he advised clients across a range of industries on European and German merger control, antitrust and cross-border litigation. Rainer is also a visiting professor at Heidelberg University and has published and spoken widely on issues of competition policy, general EU law and comparative law. Born in 1969, he studied law, and Spanish & French literature at universities in Germany, Spain and Canada, and holds Ph.D. (Trier), LL.M. (McGill) and Ass./Ref. iur. (Rh.-Pfalz) degrees. He is fluent in German, English, French and Spanish.

Jules Fabre, Legal Director, Pinsent Masons France

Jules Fabre is a Life Sciences & IP Legal Director (Counsel) at Pinsent Masons in Paris. He has extensive experience handling complex French and cross border patent and SPC litigations, both in private practice and in-house, particularly in relation to pharmaceuticals, medical devices and biotechnologies. Jules also has broad experience advising on transactional matters such as collaboration and R&D agreements. Before joining Pinsent Masons, Jules was a Senior Counsel in the European IP and Regulatory Litigation team at Teva Pharmaceuticals, where he coordinated pan-European launch strategies and patent litigations. Jules also previously worked at Linklaters and Hogan Lovells in Paris. Legal 500 France 2022 named Jules a rising star in patent litigation and next generation partner in Healthcare and Life Sciences.

Cecile Teles, Head Patent Attorney, Zentiva

Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry. Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house as at elite innovator company (Sanofi), biologics (Merck Serono) and extensive generic experience she gained as Zentiva. Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi. She is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.

Brian Malkin, Partner, McDermott Will & Emery LLP

Brian Malkin is a partner in McDermott Will & Emery's FDA practice. He counsels pharmaceutical and biologic clients on Food and Drug Administration (FDA) regulatory matters and intellectual property (IP) law, with an emphasis on patent litigation. His practice at the intersection of FDA- regulated products and patent law makes him a valuable partner to drug manufacturers, biotechnology clients, medical device companies and cannabis companies as they develop new products and protect their innovations though life cycle management, bring their products to market and pursue transactional opportunities.Brian's regulatory experience includes all types of FDA-regulated products: drugs and biologics (including animal drugs and biologics), medical devices, cannabis, foods and dietary supplements, cosmetics and tobacco products. He is a key advisor to pharmaceutical and biologic clients in the premarket, regulatory review, and marketing, enforcement and lifecycle management phases of product development.

Saufung Ma, Accord Healthcare

Gustaf Duhs, Partner and Head of Competition and Regulatory, Stevens & Bolton LLP

Gustaf is head of the competition and regulatory practice at Stevens & Bolton and has a particular focus on life sciences. He has worked in the UK competition and consumer regulator. Experience includes working on the first infringement decision in the pharmaceutical sector under the modern UK competition regime and the first excessive pricing infringement decision. Gustaf has successfully judicial reviewed UK government policy on the importation of pharmaceuticals and advised on a huge variety of public law issues, including assisting companies and public bodies to navigate the unique and varied consequences of Brexit. He routinely advises on a range of commercial agreements and regulatory issues.

Agnieszka Deeg-Tyburska, Head of Legal, General Counsel, Commercial Proxy at Polpharma

Agnieszka Deeg-Tyburska has been working as the Chief Legal Advisor of the Polpharma Group since 2015. Currently, he manages the legal, organizational, compliance, security and patents teams. She is also the Vice-President of the Legal Committee of Medicines for Europe. Since 2022 she holds the title of Certified CERP Mediator. Agnieszka has been associated with the pharmaceutical industry for many years, representing generic and innovative producers in regulatory and patent related matters as well as in large and sophisticated transactions. She has extensive experience in M&A transactions with particular emphasis on acquisitions of public companies, investment transactions of venture capital funds. Email: agnieszka.deeg-tyburska@polpharma.com

Jennifer Sunderland, Senior Patent Litigation Counsel, Viatris

Jennifer Sunderland is Senior Patent Litigation Counsel at Viatris. Viatris is a global pharmaceutical company with a large product portfolio and an active legal team. Jennifer's practice covers a wide range of IP and litigation related issues in the pharma sphere for all countries outside North America and Canada. Her main focus is on innovative strategy for, and coordination of, pan-European patent litigation with the aim of securing the market for new and existing products.

Jurgen Figys, Counsel, Crowell & Moring

Jurgen Figys is a senior counsel in Crowell & Moring's Brussels office and a member of the Intellectual Property Group. Jurgen is one of the few lawyers in Belgium also to be trained as a biomedical scientist. He is therefore able to combine his scientific reasoning with his legal knowledge, a considerable asset in the technology-driven IP field. Jurgen predominantly works with clients in the pharmaceutical and biotechnology industry, with a particular focus on complex patent litigation and regulatory advice. He has particular experience in patent litigation with regard to invalidity, third-party opposition proceedings against counterfeit seizure, and preliminary injunction proceedings. His pre-contentious experience includes freedom-to-operate patent analysis and drafting protective letters. Jurgen is also involved in a number of trademark cases, such as parallel import litigation. Within life sciences, Jurgen provides strategic regulatory advice to pharmaceutical and biotech companies as well as national and European industry associations. His experience covers a broad range of regulatory issues like data exclusivity, EU marketing authorizations, pricing and reimbursement of medicinal products, advertising, medical devices, clinical trials, and data. Digital transformation in the health sector is also one of his main focus areas. Thanks to his scientific background, Jurgen is also able to advise clients on other EU regulatory issues with a technical angle. For example, Jurgen has an impressive, substantive knowledge of REACH through his work for a wide range of U.S. and EU-based clients. He also regularly advises on CLP issues. In addition, he assists clients with their more science-driven submissions to the European Chemicals. Prior to joining Crowell & Moring, Jurgen worked for ten years at the Free University of Brussels as a Ph.D. student and as a director of successive scientific studies for the Belgian Ministry of Defense, performing research on cell metabolism, apoptosis and cancer physiology.

Michael Frisby, Partner, Stevens & Bolton LLP

Michael is a partner in the dispute resolution practice at Stevens & Bolton with particular expertise in the life sciences sector. Michael has extensive experience of providing life sciences companies with risk management advice and handling disputes across a broad range of issues in the courts and in international arbitration, seated in London and abroad. His work has included handling various supply chain disputes, including claims for force majeure and frustration, specific performance and obtaining damages for breach of contract in both litigation and international arbitrations. He has obtained orders for rectification and declarations as to meaning of contracts. His regulatory work has included judicial review against NICE guidelines and also UK government policy and handling dawn raids. His fraud work has included obtaining freezing and delivery up orders in the English Courts and in courts abroad to recover stolen assets and money. He has also advised clients in relation to defective product issues and claims arising. Michael is ranked as a "Leading individual" by The Legal 500 for life sciences in the UK. He is also included in The Legal 500 "Hall of Fame" and is ranked in Band 1 by Chambers UK. He is listed in the latest edition of The Best Lawyers in the United Kingdom. He is a CEDR Accredited Mediator and a Fellow of the Chartered Institute of Arbitrators.

Jan Truijens Martinez, Counsel, Stibbe

Jan Truijens Martinez is a counsel in Stibbe's antitrust practice. With his expertise in all areas of EU and Dutch competition law, Jan advises multinational companies active in numerous industries, with a particular focus on the pharmaceutical sector. Over the past years, Jan has advised on a wide range of topics in this industry, ranging from the abuse of a dominant position, policies on parallel import and a number of high profile multi-national pharmaceutical mergers and acquisitions.

Catherine Drew, Partner, Pinsent Masons

Catherine is a patent and regulatory Life Sciences specialist with a degree in pathology. She has over fifteen years' experience advising on pan-European patent litigation and administrative litigation concerning all exclusivity rights attaching to pharmaceutical products. Catherine has represented clients before all courts in England & Wales and before the European General Court & Court of Justice in precedent setting litigations. In addition, Catherine advises on the interpretation of UK and European regulations relating to medicinal products, medical devices, cosmetics, borderline products and similar consumer products providing strategic advice to clients seeking to bring products to market. Having undertaken two secondments at a global pharmaceutical company, one leading the patent litigation team, Catherine has a deep understanding of the industry, commercial drivers and markers of success for companies operating in the life sciences sector.

Robert Vidal, Partner, Pinsent Masons

Robert is a Partner in the Competition, EU & Trade team at Pinsent Masons specialising in competition law and its interplay with IP. He was the Head of Competition at Taylor Wessing for over 12 years and has almost 25 years of experience advising in the life sciences sector. Regularly advises on abuse of dominance cases, competition law litigation, merger control and joint ventures. Robert provides outstanding expertise across the life sciences sector and acted across a number of novel, precedent setting cases including the defining case on ""pay for delay"" before the Court of Justice of the European Union. Robert has been involved in various successful stand alone and follow-on damages actions, for both claimants and defendants, before the High Court and the Competition Appeals Tribunal. This includes advising innovators and generics on the application of competition law to various divisional patent strategies. Recommended Lawyer in Legal 500 2021: "a standout partner, with great understanding of what we're trying to achieve and of our business and sector. He also has an innovative approach to new things - a shrewd life sciences and litigation hire." Previous comments: "Strategically excellent", "particularly good at ensuring focus is kept on a client's priorities". "Is particularly strong in the life science and tech sectors", "skills and presentation with clients are far and above any competitors", is "one of the most talented competition lawyers of his generation, possessing drive, energy, and a fanatical devotion to his client". Leading Individual in Chambers: Previous comments: "strategically excellent" can "think outside the box" and "sees things from his client's business perspective". "His key strength is his unparalleled command of competition law in the UK and in other EU jurisdictions". Competition Litigation, Chambers: "a rare combination

José Angel García-Zapata, Senior IP Counsel, Insud Pharma

Senior IP Counsel at Insud Pharma. Before joining the company in 2020 he worked during ten years as an associate at the IP department of Bird & Bird LLP in Madrid, with main focus in patent litigation, but also trademarks, unfair competition and advertising matters, both contentious and non-contentious. As an inhouse counsel, he works on the strategies to secure the manufacture and launch of generic and biosimilar products, coordinate patent litigation cases in different jurisdictions, coordination with partners and licensing issues.

Kristin Cooklin, Head of Intellectual Property, Zentiva Group

Kristin Cooklin is the Global Head of Intellectual Property at Zentiva in Prague. Kristin and her team are responsible for supporting clients with respect to all IP Issues at all stages- including development, in-licensing, litigation and launch. In 2014 she joined Novartis where she held several different roles in its Sandoz Division in Munich, Germany, most recently as the Global Head of IP Litigation ex-US. In 2018 Kristin left Novartis to join the Zentiva and lead and transform the IP team after divestment from Sanofi. Prior to going in-house at Novartis Kristin spent over a decade in Washington DC working in AmLaw 100 law firms as a patent litigator, focusing primarily on pharmaceutical and life sciences litigation. Kristin is a US attorney at law and patent attorney. She has handled counseling, litigation and launches of pharmaceutical products across the world with a focus on the US and Europe and was responsible for the successful IP strategy and launch of several of the first biosimilar products launched around the world.

Raphaël De Coninck, Vice President, Charles River Associates

Dr. Raphaël De Coninck heads the Brussels office of the global economic consulting firm Charles River Associates (CRA). Raphaël provides expert economic evidence and testimony in all competition matters, leading teams of economists at the forefront of merger, antitrust and damages analysis. He has worked on many of the landmark European competition cases of the last two decades, including over 80 mergers and 25 "Phase II" merger investigations, and over 50 abuse of dominance, cartel and damages cases. In addition to his expertise in European Commission matters, Raphaël has provided expert economic evidence in Belgium, the United Kingdom, France, the Netherlands, Spain, Switzerland, and in the United States. Raphaël has acquired deep experience in the life science space, advising leading pharmaceutical firms in mergers and antitrust investigation as well as damages cases on issues such as excessive pricing and exclusionary conduct (including disparagement and the misuse of patents to delay generic entry). Raphaël has published numerous articles on the economics of competition, including on the assessment of competitive effects linked to innovation in the pharmaceutical sector. He was also the lead author of a study commissioned by the European Commission (DG Grow) on exemption provisions during patent and SPC protection in Europe. Raphaël holds a Ph.D. in economics from the University of Chicago and degrees in law and in economics from the University of Liège, Belgium. He has been a post-doctoral fellow at New York University and taught at the University of Chicago and the Free University of Brussels (ULB). Raphaël is recognized as one of Europe's top competition economists by WWL Global Elite.

Javier Huarte, Partner, Grau & Angulo

Javier Huarte is a partner at IP law firm Grau & Angulo. His professional practice focuses on pharmaceutical patents, advising and representing multinational and national companies on a range of contentious matters, including pan-European strategies. A very active litigator, since 2001 he has been permanently involved in landmark patent and SPC court cases regarding blockbuster drugs such as simvastatin, paroxetine, finasteride, amlodipine, escitalopram, sildenafil, telmisartan + hctz, pregabalin, rivastigmine, drospirenone, quetiapine, ibandronate, valganciclovir, bosentan, rituximab, valsartan/amlodipine, fulvestrant, tenofovir/emtricitabine, ezetimibe/simvastatin, insulin glargine, sorafenib and many more. Javier's status as a leading lawyer in Spain is widely acknowledged and he is lauded by judges and peers alike, featuring as a leading lawyer in the top international directories for patents and life sciences.

Corinna Sundermann, Senior Vice President Intellectual Property, Fresenius Kabi

Corinna Sundermann is heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 40 FTE since then. She is Senior Vice President since 2012 and took over responsibility for copyright within Fresenius as well. Focus concerning patents is on generics, branded products, clinical nutrition and medical devices. Characteristic for the department is, to a certain extent, internal handling of litigation. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and is European Patent Attorney since 2006. She holds a Dr. rer. nat. from the University of Jena and a diploma in chemistry from the University of Frankfurt.

Imre Gonda, Head of IP department, Gedeon Richter

Imre Gonda has been practicing national and international IP law for more than 20 years. Currently he is the director of Legal and IP Department one of the largest pharmaceutical company in the Central European region which is very active in both areas, research of originating pharmaceuticals and generic product development. Previously he was head of Industrial Property Department. Before he joined Gedeon Richter Plc., he filled different positions in the Hungarian Intellectual Property Office, for 10 years he was the deputy-head of Trademark, Model and Design Department. He was responsible for managing and supervising the operation of national and international trademark, geographical indication and design sectors. He was involved in norm setting procedures including the preparation of amendments of laws and the creation of new international legal instruments. He participates in different international forums on a regular basis at WIPO and EU institutions, he was the elected vice-chair for eight cycles of the WIPO Standing Committee on the laws of Trademarks, Designs and Geographical Indications which forum was chaired by him for two years. He was participating in different forums of EUIPO (e.g. Management Board and Budget Committee; Liaison Meeting) in his national capacity for a considerable time period. He is qualified as a lawyer in Pázmány Péter Catholic University (Budapest) and did post graduate studies in European Law (LLM). He has written and edited a number of publications and books.

Michele Uda, Director, Egualia

Italian association for accessible medicines, official representative body of the generic, biosimilar and value added medicines in Italy - MEMBER of the Executive Committee of Medicines for Europe - CHAIRMAN of the NAC (National Association Committee of Medicines for Europe). Graduated in Political Science from the International University LUISS Guido Carli in Rome, with a specialization in International Economics, after an initial experience in one of the largest Italian trade unions, he has successfully completed a full time MBA in International Business and Economics at "Mib School of Management" of Trieste. He then continued his career in the retail consumer sector at Ferrero Italy as Assistant Brand Manager for the Italian multinational company's core business and, later, at Colgate Palmolive Italy as a market and industry sales analyst in the Household Care division.

He stepped into the healthcare sector joining Johnson & Johnson Medical where he was responsible for direct management of sales and marketing for the breast care line in Italy's central and southern regions. From March 2007 he joined EGUALIA (formerly known as Assogenerici, the Italian Generic and Biosimilar Medicines Association), as "Pharmaceutical Economics & Policy Affairs Manager", assuming direct responsibility of the Centre for Economics and Policy Analysis of the association. From April 2012 he has been appointed Director General of EGUALIA, keeping also the responsibility for international relations. Since 2014 is also managing IBG – Italian Biosimilars Group, representing the biosimilar medicines industry within EGUALIA and more recently the VAM – Value Added Medicine Group of EGUALIA. Member of the Executive Committee of Medicines for Europe (European Generic & Biosimilars Medicines Industry Association); appointed Chairman of the GMAC (Generic Market Access Committee of Medicines for Europe) in 2011, he is now Chairman of the NAC (National Association Committee of Medicines for Europe).

Adrian van den Hoven, Director General, Medicines for Europe

Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, foster access to medicine, support policy measures for sustainable pricing, promote efficient regulatory standards and develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Adrian is the former President (and current Member of the Board) of the European Medicines Verification Organisation (EMVO) for the implementation of serialisation against falsified medicines. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations Industry departments. He previously worked as a researcher in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.

Stella Kyriakides, Commissioner, Health and Food Safety, European Commission

Ms Kyriakides, in her capacity as the European Commissioner for Health and Food Safety since December 2019, is leading the Commission's work on various portfolios including the Europe's Beating Cancer Plan, aiming to improve cancer prevention and care while also she is in charge of developing a new Pharmaceutical Strategy to ensure that Europe can meet its needs relating to affordable medicines. During the COVID-19 crisis, the Commissioner took on the responsibilities of coordinating the EU's health response and of supporting Member States to tackle the outbreak.

Ms. Kyriakides has previously worked as a clinical psychologist for 28 consecutive years, in the Mental Health Services of the Ministry of Health of the Republic of Cyprus in the area of Child and Adolescent Psychiatry, from 1979-2006.

Ms. Kyriakides was elected to the Cyprus Parliament in 2006 and was then re-elected in 2011 and 2016 for the Democratic Rally Party, for which she served duties as Vice-President. In 2012, Ms. Kyriakides was appointed Head of the Cyprus Delegation to the Parliamentary Assembly of the Council of Europe (PACE) and in 2017 she was elected as President of PACE, thus becoming the 30th President of the Assembly. Notably, she was also the founder of the First Breast Cancer advocacy organization in Cyprus, namely "Europa Donna – Cyprus" and served as the President from 2000-2015. She was also President of the European Breast Cancer Coalition Europa Donna.

Ingrid Sollerer, General Counsel & Global Head Legal, Sandoz

Dr. Ingrid Sollerer is Global Head Legal and General Counsel at Sandoz. She joined Sandoz GmbH, Austria in April 1998 and moved on to Novartis International AG in Basel, Switzerland where she held the position of a Senior Corporate Counsel, Mergers & Acquisitions and Competition Law from 2001 to 2007. Since 2008 she was heading the Legal Departments for Western Europe, Middle East/Africa, the global Business Units Oncology Injectables and Anti-Infectives and holding the position of the Global Head Legal Biopharmaceuticals and Deputy General Counsel at Sandoz. In 2016 she joined Novartis Oncology as Global Head Legal Transactions and Cell&Gene in East Hanover,USA before rejoining Sandoz in 2019 in her current role. Ingrid holds a degree of law from the University of Innsbruck, a Diploma of international law at the University of Seville/Spain and obtained a doctorate in law in 2001 at the University of Innsbruck.

Ana Martí, General Counsel & IP, Medichem

Ana Martí is General Counsel at Medichem, S.A., a Spanish headquartered company devoted to the development and manufacture of active pharmaceutical ingredients and generic medicines. Her role includes, in addition to legal, IP and regulatory affairs of the group of companies. She has more than 20 years' experience in the pharmaceutical industry, mainly acquired in the generic sector. She is qualified as a Spanish attorney at law and completed executive education at ESADE Business School. Before joining Medichem, she worked several years at a Spanish law firm advising life science clients on commercial transactions and regulatory and IP matters. Ana has also participated as co-author of a book on pharmaceutical marketing and is currently member of the Board of Medicines for Europe.

Tomos Shillingford, General Counsel, InsudPharma

Tom is General Counsel at Insud Pharma, a diversified biopharmaceutical business based in Madrid, Spain. Tom's previous positions were as Director IP Litigation at Insud Pharma and Allergan. Tom is a triple qualified lawyer (England and Wales, Australia, Spain), whom previously worked in private practice in London with Bird & Bird and in Melbourne with Herbert Smith Freehills. Tom has been working in the pharmaceutical industry for over 13 years and has a wealth of experience in patent litigation and pharmaceutical law across the globe. In his previous role, Tom managed many prominent patent actions, including Actavis v Sanofi (Irbesartan HCT), Actavis v Boehringer Ingleheim (Telmisartan HCT), Actavis v Warner Lambert (Pregabalin) and Actavis v Eli Lilly (Pemetrexed).

Bibianne Bon, General Counsel Europe, Teva

Bibianne Bon is SVP & General Counsel Europe at Teva. She currently leads Teva's European legal team responsible for the legal support to the commercial organizations, as well as the manufacturing and R&D sites in Europe. She joined Teva in 2010 from Allen & Overy LLP, where she specialized in corporate and commercial law. Initially, Bibianne focused on corporate and corporate governance matters; she has worked on many of Teva's acquisitions. Over the years, Bibianne gained broad pharmaceutical experience while supporting various European markets and acted as General Counsel Benelux before her current role. Bibianne has a Master degree in European, International and Dutch law from the University of Groningen, the Netherlands.